RxDoctor Payments Data

Alan Goldberg, MD

Pulmonary Disease · Hampton, VANPI 1700851078

Payments from drug & device makers

$5,170in general payments, 2019–2025

Across 125 payments — averaging $41.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • GSK$635
  • Genentech USA, Inc.$299
  • Jazz Pharmaceuticals Inc.$224
  • Baxter Healthcare$194
  • plus $862 from 8 others

What the payments were for

  • Food & beverage$5,164100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,170 in reported general payments places this provider in the 60th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$87,563
Medicare patients
674
Services billed
1,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter359$345,404
Aralast NpAlpha-1-Proteinase Inhibitor12$170,437
Spiriva RespimatTiotropium Bromide102$91,613
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$42,428
Breo ElliptaFluticasone/Vilanterol73$39,744
Stiolto RespimatTiotropium Br/Olodaterol Hcl65$39,047
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$26,151
Arnuity ElliptaFluticasone Furoate74$25,209
SymbicortBudesonide/Formoterol Fumarate48$23,743
Advair HfaFluticasone Propion/Salmeterol32$23,500
DuleraMometasone/Formoterol38$20,905
Incruse ElliptaUmeclidinium Bromide19$18,059
Fluticasone-SalmeterolFluticasone Propion/Salmeterol73$16,487
Albuterol Sulfate HfaAlbuterol Sulfate399$13,450
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate39$8,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$635$454,566568 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,313$130,660167 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,643$66,17297 claims
MerckDulera$106$20,90538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Hampton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →